The biopharmaceutical contract manufacturing (CMO) and contract research organizations (CRO) provide services for manufacturing biologics, vaccines, monoclonal antibodies, gene therapies and other therapeutics for biopharmaceutical companies. The biopharmaceutical companies outsource their needs for cell line development, protein expression and purification for efficient development and manufacturing of biotherapeutics.
The global biopharmaceutical CMO and CRO Market is estimated to be valued at US$ 41.71 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The outsourcing trend among the biopharmaceutical companies is a major driver of growth in the biopharmaceutical CMO and CRO market. As biotherapeutic development involves complex bioprocessing steps, many smaller biopharma companies lack required infrastructure and expertise for activities like mammalian cell culture, purification and downstream processing. Larger biopharma companies also find it more cost-effective to outsource non-core activities to contract service providers. The CMOs and CROs provide flexible, scalable solutions tailored to client's development and manufacturing needs. This enables biopharma companies to focus on drug discovery and clinical development while ensuring timely supply of biologics.
Segment Analysis
The biopharmaceutical CMO and CRO market is segmented on the basis of end user, type and service. The service segment dominates the market as CMOs and CROs offer various services to biopharma companies such as clinical trial services, consulting services, manufacturing services, and non-clinical services. Clinical trial services acquire the major share under service segment owing to increasing clinical trials for biologics and biosimilars every year.
Key Takeaways
The global biopharmaceutical CMO and CRO market analysis is expected to witness high growth during the forecast period of 2024 to 2031. The global biopharmaceutical CMO and CRO Market is estimated to be valued at US$ 41.71 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031.
Regional analysis shows that North America dominates the market and is expected to continue its dominance during the forecast period. This is due to presence of well-established CMOs, CROs and biopharma companies in countries like US and Canada. Asia Pacific is expected to be the fastest growing region mainly due to increasing investment by governments and companies in pharmaceutical and biotechnology sector.
Key players operating in the biopharmaceutical CMO and CRO market are Albemarle Corporation, Greenchemicals S.r.l., ICL, Jordan Bromine Company, Kingboard Holdings Limited, LANXESS, Novel Chem, Shandong Brother Sci. & Tech. Co., Ltd., Shandong Futong Chemical Co., Ltd. and Tianjin Changlu Hangu Saltern Co., Ltd. Albemarle Corporation acquires majority share and is expanding its manufacturing and service capabilities globally through acquisitions and collaborations to strengthen its leadership position in the market.
Get more insights on this topic: https://www.newswirestats.com/biopharmaceutical-cmo-and-cro-market-industry-insights-trends-biopharmaceutical-cmo-and-cro-market/
Comments
0 comment